Metabolic effects of nigrostriatal denervation in basal ganglia

Trends in Neurosciences

Volumn 23, Issue 10 SUPPL., 2000, Pages

  Hirsch, Etienne C ^a   Périer, Céline ^a   Orieux, Gaël ^a   François, Chantal ^a   Féger, Jean ^a   Ome Yelnik, Jerome ^a   Vila, Miquel ^a   Levy, Richard ^a   Tolosa, Eduardo S ^c   Marin, Concepcio ^e   Herrero, M Trinidad ^b   Obeso, José A ^d   Agid, Yves ^a  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b UNIVERSITY OF MURCIA   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d UNIVERSITY CLINIC OF NAVARRA   (Spain)

^e Fundacio Clinic   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN ELECTROPHYSIOLOGY; DENERVATION; HUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; REVIEW; STRIATONIGRAL DEGENERATION; SUBTHALAMIC NUCLEUS; THALAMUS PARAFASCICULAR NUCLEUS;

EID: 0033677878     PISSN: 01662236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1471-1931(00)00021-5     Document Type: Review

References (53)

1. Levodopa in the treatment of Parkinson's disease: A consensus meeting
2. Levodopa-induced dyskinesias in Parkinson's disease: Phenomenology and pathophysiology
3. Biochemistry of Parkinson's disease 28 years later: A critical review
4. Long-term electrical inhibition of deep brain targets in movement disorders
5. The functional anatomy of basal ganglia disorders
6. Primate models of movement disorders of basal ganglia origin
7. Pathophysiology of parkinsonian motor abnormalities
8. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced parkinsonism
9. Effects of L-DOPA on neuronal activity of the globus pallidus externalis (GPe) and globus pallidus internalis (GPi) in the MPTP-treated monkey
10. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey
11. Changes in local cerebral glucose utilization associated with Parkinson's syndrome induced by 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the primate
12. Local cerebral metabolic effects of L-dopa therapy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in monkeys
13. Cerebral metabolism of parkinsonian primates 21 days after MPTP
14. Neural mechanisms underlying parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4 phenyl-1,2,3,6-tetrahydropyridine
15. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP
16. Neuronal expression of nuclear and mitochondrial genes for cytochrome oxidase (CO) subunits analysed by in situ hybridization: Comparison with CO activity and protein
17. Mitochondrial and nuclear gene expression for cytochrome oxidase subunits are disproportionately regulated by functional activity in neurons
18. Consequences of nigrostriatal denervation on the functioning of the basal ganglia in human and nonhuman primates: An in situ hybridization study of cytochrome oxidase subunit I mRNA
19. Re-evaluation of the functional anatomy of the basal ganglia in normal and parkinsonian states
20. Effects of nigrostriatal lesions on the levels of messenger RNAs encoding two isoforms of glutamate decarboxylase in the globus pallidus and entopeduncular nucleus of the rat
21. Consequences of nigrostriatal denervation and L-dopa therapy on the expression of the glutamic acid decarboxylase messenger RNA in the pallidum
22. Increased subthalamic neuronal activity after nigral dopaminergic lesion independent of disinhibition via the globus pallidus
23. Convergence of subthalamic and striatal efferents at pallidal level in primates: An anterograde double-labeling study with biocytin and PHA-L
24. Efferent projections of the subthalamic nucleus in the rat: Light and electron microscopic analysis with the PHA-L method
25. Intracellular study of rat globus pallidus neurons: Membrane properties and responses to neostriatal, subthalamic and nigral stimulation
26. Functional anatomy of the basal ganglia. 1. The cortico-basal ganglia-thalamo-cortical loop
27. Excitotoxic acid lesions of the primate subthalamic nucleus result in reduced pallidal neuronal activity during active holding
28. Excitatory influence of rat subthalamic nucleus to substantia nigra pars reticulata and the pallidal complex: Electrophysiological data
29. Metabolic activity of excitatory parafascicular and pedunculopontine inputs to the subthalamic nucleus in a rat model of Parkinson's disease
30. Pedunculopontine nucleus in the squirrel monkey: Projections to the basal ganglia as revealed by anterograde tract-tracing methods
31. On the relationships between the striatum and the pedunculopontine tegmental nucleus
32. Regional metabolic changes in the pedunculopontine nucleus of unilateral 6-hydroxydopamine Parkinson's models rats
33. Plasticity of nerve afferents to nigrostriatal neurons in Parkinson's disease
34. The pedunculopontine nucleus in Parkinson's disease
35. The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease
36. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson's disease and in progressive supranuclear palsy
37. Evidence that the parafascicular projection to the subthalamic nucleus is glutamatergic
38. Electrophysiological study of the excitatory parafascicular projection to the subthalamic nucleus and evidence for ipsi- and contralateral controls
39. Systemic administration of NMDA and AMPA receptor antagonists reverses the neurochemical changes induced by nigrostriatal denervation in basal ganglia
40. Excitatory amino acid binding sites in the basal ganglia of the rat: A quantitative autoradiographic study
41. Excitatory amino acid receptors in the brain: Membrane binding and receptor autoradiographic approaches
42. Pharmacological study of the cortical-induced excitation of subthalamic nucleus neurons in the rat: Evidence for amino acids as putative neurotransmitters
43. Localization of striatal excitatory amino acid binding site subtypes to striatonigral projection neurons
44. Towards an understanding of the role of glutamate in experimental parkinsonism: Agonist-sensitive sites in the basal ganglia
45. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys
46. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys
47. MK-801 prevents levodopa-induced motor response alterations in parkinsonian rats
48. Functional activity of zona incerta neurons is altered after nigrostriatal denervation in hemiparkinsonian rats
49. Patterns of connections between zona incerta and brainstem in rats
50. Evidence that projections from substantia innominata to zona incerta and mesencephalic locomotor region contribute to locomotor activity
51. AMPA glutamate receptor activation in the posterior zona incerta inhibits amphetamine and apomorphine-induced stereotypy
52. AMPA/kainic acid glutamate receptor antagonism in the zona incerta dorsal to the subthalamic nucleus inhibits amphetamine-induced stereotypy but not locomotor activity
53. Activation of AMPA/kainic acid glutamate receptors in the zona incerta stimulates locomotor activity